1-(Methylsulfonyl)piperazine → HCID 44545154, 화합물

HRID 2093398노트

반응식

HRID 2093398 반응식
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26](O)=[O:27])=[C:17]([N:29]3[CH2:34][CH2:33][O:32][CH2:31][CH2:30]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[CH3:35][S:36]([N:39]1[CH2:44][CH2:43][NH:42][CH2:41][CH2:40]1)(=[O:38])=[O:37]>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][CH2:25][C:26]([N:42]3[CH2:43][CH2:44][N:39]([S:36]([CH3:35])(=[O:38])=[O:37])[CH2:40][CH2:41]3)=[O:27])=[C:17]([N:29]3[CH2:30][CH2:31][O:32][CH2:33][CH2:34]3)[N:16]=2)=[CH:13][N:14]=1

참가 물질

3

반응물 2

HCID 7091611-(Methylsulfonyl)piperazineHCID 66909826HCID 66909826, 화합물

생성물 1

HCID 44545154HCID 44545154, 화합물

실험 절차

3-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)propanoic acid (50 mg) was reacted with 1-(methylsulfonyl)piperazine via General Procedure F followed by Boc deprotection via General Procedure E to give 33.8 mg 112 as white solid following reverse phase purification. MS (Q1) 517.2 (M)+

후처리

  1. customto give
  2. custom33.8 mg 112 as white solid following reverse phase purification

출처 및 근거

ORD 기록
ord-02536a162c0b41d6ae737261c13a0d73
출처 데이터셋
uspto-grants-2013_05
특허 번호
US08445487B2

반응 노트

불러오는 중…